Skip to main content

Head and neck cancer

11-09-2017 | Head and neck cancer | News | Article

ESMO 2017

Regorafenib improves outcomes in relapsed glioblastoma patients

The phase II REGOMA trial shows that patients with recurrent glioblastoma derive a significant overall survival and disease control benefit from treatment with regorafenib over lomustine.

05-09-2017 | Oncology | News | Article

KEYNOTE-028 results point to pembrolizumab efficacy in SCLC, nasopharyngeal cancer

Findings from the multicohort, phase Ib KEYNOTE-028 trial indicate that pembrolizumab elicits durable responses and is well tolerated in patients with extensive-stage small-cell lung cancer and those with recurrent or metastatic nasopharyngeal carcinoma.


J Clin Oncol 2017; Advance online publication

24-08-2017 | Head and neck cancer | News | Article

Editor's pick

EBV DNA positivity may signify asymptomatic nasopharyngeal carcinoma

Patients with plasma samples repeatedly positive for Epstein–Barr virus DNA should undergo further screening for nasopharyngeal carcinoma, researchers report.


N Engl J Med 2017; 377: 513–522

11-08-2017 | Head and neck cancer | News | Article

Editor's pick

Mutation-directed CAR T cell therapy feasible in recurrent glioblastoma

Treatment with autologous chimeric antigen receptor T cells directed against the epidermal growth factor receptor variant III mutation is feasible and well tolerated in patients with recurrent glioblastoma, indicates a first-in-human study.


Sci Transl Med 2017; 9: eaaa0984

06-06-2017 | Head and neck cancer | News | Article

ASCO 2017

HPV vaccination ‘tremendous potential’ for prevention of oral HPV infection

Routine vaccination against human papillomavirus has “tremendous potential” for reducing the risk of oral HPV infection and associated malignancy, suggests research presented at the 2017 American Society of Clinical Oncology annual meeting, held in Chicago, Illinois, USA.


J Clin Oncol 2017; 35: 6003

23-05-2017 | Head and neck cancer | News | Article

Editor's pick

Recommendation against routine thyroid cancer screening retained

In a statement published in JAMA, the US Preventive Services Task Force upholds its 1996 recommendation against screening for thyroid cancer among asymptomatic adults.


JAMA 2017; 317: 1840–1841, 1882–1887, 1888–1903, JAMA Otolaryngol Head Neck Surg 2017; Advance online publication, JAMA Surg 2017; Advance online publication

image credits